A Phase 11 Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women with ER-Positive/HER2-Negative, Early Stage Breast Cancer - Stand Up To Cancer

Blog

Posted October 14, 2019

A Phase 11 Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women with ER-Positive/HER2-Negative, Early Stage Breast Cancer

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.